TNIB Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech,

New Post Public Reply Private Reply Replies (0) Message Board

Oct 11, 2012 at 3:17 PM

[b]TNIB >Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer[/b]

2012-10-11 07:30 ET - News Release

NEW YORK, NY and POTOMAC MD -- (Marketwire) -- 10/11/12

TNI BioTech, Inc. (PINKSHEETS: TNIB), a public company operating in the biotech sector, announced today the signing of an agreement with Pharmaceutical Care Consultants of South Florida, d/b/a Skip's Pharmacy. Under the agreement, Dr. Henry "Skip" Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for TNIB's pharmaceutical plant in Managua, Nicaragua. Dr. Lenz will be responsible for leading the company's global manufacturing development.

Dr. Lenz will join the company's executive leadership team, and report to Noreen Griffin, CEO and Dr. Eugene Youkilis, President of TNI BioTech, Inc. As the company's Quality Control Officer, Dr. Lenz will be responsible for assuring all manufacturing meets cGMP standards. Dr. Lenz has held senior management positions in quality control, quality assurance and production for several international manufacturers. In addition, Dr. Lenz held senior clinical research pharmacist positions with both domestic and international clinical research groups, including Senior Researcher at Key Pharmaceuticals in charge of the Research Division. Dr. Lenz founded and ran a contract research company producing over 10 patents before being acquired by a mid-sized manufacturing company. Over the last fifteen years Dr. Lenz has set his sights on relieving HIV/AIDS by participating in clinical applications of several novel therapies.

Dr. Lenz is a graduate of The Massachusetts College of Pharmacy and the University of Florida. Currently, he owns Pharmaceutical Care Consultants of South Florida d/b/a Skip's Pharmacy in Boca Raton, Florida with his partner Phil Giordano. Skip's Pharmacy is dedicated to providing the highest quality and optimum pharmaceutical care through its unique ability to formulate and compound drugs specifically to meet patient's needs. Skip's Pharmacy has been the leading outlet for the supply of LDN for over ten years.

Noreen Griffin, TNI BioTech, Inc.'s CEO, noted the company's hiring of Dr. Lenz and his partners continues to reflect TNI BioTech's commitment to deliver a quality product and to become a world-class leader in innovative therapeutics for patients afflicted with autoimmune and infectious diseases such as cancer and HIV/AIDS.

Dr. Lenz stated, "I was pleased to see that TNIB was taking the manufacturing and distribution of IRT-103 (LDN) seriously. It is important that IRT-103 (LDN), a treatment that has done so much good for some any people, be available at a quality and a price that benefits everyone."

About TNI Biotech, Inc.

TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.

Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:

Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
As an adjunct to antibiotics in the treatment of infectious diseases;
In cancer patients undergoing chemotherapy, radiation treatments or surgery;
Patients with AIDS, in combination with retroviral drug therapy; and
In wound healing or herpes viral infections.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

See http://www.tnibiotech.com for more information.

Contact:

Global Investment Media

Phone: 310-353-6277

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CourseArc Partners with Colleges for ADA Compliance

CourseArc's Landmark Deal with Public Colleges Well, slap me silly and call me a believer—looks like CourseArc just locked down a heck of a gig with a public college system that's head-over-heels squirming to meet shiny new accessibility demands. Nearly 200,000 learners are waiting at their gates, and this agreement is the lifeline for colleges to not only stay afloat...

AI Agents Race: 10M Downloads Spark Competitive Fire

The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...

Anita Eno: 2027's Top Trailblazing Businesswoman

Anita Eno's Well-Deserved Recognition You've got to respect a story where someone claws their way up from humble beginnings to a position of serious influence. Anita Eno, Founder and CEO of Prayers Are Answered Inc., is one of those impressive figures, recently bagging the 2027 American Business Woman of the Year title. This accolade, dished out by the American Business...

York Space Systems Faces Securities Law Class Action

Unexpected Turbulence at York Space Systems Just when you thought things might be smooth sailing, York Space Systems (NYSE: YSS) finds itself on the hot seat. This fledgling aerospace player is now wrangling with a class action lawsuit for allegedly breaking federal securities laws. Call it a wake-up call from DJS Law Group encouraging investors who've had their fingers...

Rublev's Tennis Meet Boosts Inclusivity for Autism

Tennis Bridging Worlds in the Heart of Kazakhstan When Andrey Rublev, a powerhouse in the world of tennis, wields his racket for more than just a win, you know something special is brewing. During the Almaty Open ATP 250 tournament, he did exactly that, sharing the court not with rivals, but with ten spirited children from the Asyl Miras Autism Center. This heartwarming...

AMTD IDEA Group: Expanding Its Global Reach

AMTD IDEA's Expansive Global Footprint While the rest of the market whirls, AMTD IDEA Group (NYSE: AMTD) is steadying itself with a comprehensive expansion that, quite frankly, demands a second look. Between weaving global media threads and dipping their toes into every alluring venture space, they've formed a tapestry not many could replicate. With facilities stretching...

Shadeform Debuts Flex VMs, Revolutionizing GPU Utilization

GPU Utilization Gets a New Spin with Flex VMs Folks, listen up: Shadeform just fired up something slick with its new Flex VMs. And, let me tell you, in today's market where GPU capacity is vanishing faster than free hotcakes on a Sunday morning, this might well be a game changer. Shadeform’s the name to remember, teaming up data center veterans with peeps who need to...

Scrutinizing M&A Deals: VREX, HZO, SYNA Under Fire?

Alignment or Deception: The M&A Alarm Bells Investors, strap in, because the world of mergers and acquisitions is lighting up like a pinball machine, and today's spotlight's on Varex Imaging Corporation (NASDAQ: VREX), MarineMax (NYSE: HZO), and Synaptics Incorporated (NASDAQ: SYNA). Halper Sadeh LLC, known for their tenacity in championing shareholder rights, has brought...

SKF Q3 2026: Margins Edge Up Amid Strategic Shifts

Cracking Open SKF's Latest Quarterly Numbers Ever seen a company limber up for a big change while tiptoeing through a minefield? That’s SKF for you in this third quarter ending September 2026. Imagine them trying to juggle a spinning platter of growth, strategic separation, and robust margins, all while balancing a wobbly market. A Close Look at Q3's Financial Feats...

University of Phoenix Lowers Costs for Transfer Students

The Pocket-Saving Game of Transfer Credits Here's the buzz: the University of Phoenix is putting some serious coin back into students' pockets through transfer credits. We're looking at more than $12,010 in savings per student, thanks to these policies, which is no chump change by any stretch. As over 900,000 credits were tossed into the pot, the savings side of education...